A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1664 participants.

Also called NCT05254002

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 1,664 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05254002
  • EU CT 2023-506981-30-00
  • EudraCT 2021-003037-11
Other papers using this trial's data
  • Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone Journal of the American Society of Nephrology : JASN, 2026-09-01 DOI, PubMed 41905767, PMC13567893 In the PMC Open Access subset under CC BY.
  • COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2025-08-01 DOI, PubMed 39916475, PMC12315800 In the PMC Open Access subset under CC BY.
  • Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes The New England journal of medicine, 2025-08-07 DOI, PubMed 40470996
  • Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial Journal of the American College of Cardiology, 2026-02-24 DOI, PubMed 41493296
  • Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure Hypertension (Dallas, Tex. : 1979), 2026-09 DOI, PubMed 42244376, PMC13480328 In the PMC Open Access subset under CC BY-NC-ND.
  • Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2025-12-23 DOI, PubMed 40886054, PMC12722168 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Canada, Denmark, France, Germany, India, Israel, Italy, Japan, Netherlands, South Korea, Spain, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05254002. Randomized; quadruple masking; primary purpose treatment. Start 2022-06-23 (actual); primary completion 2025-03-14 (actual). Results posted on 2026-07-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
Acronym
CONFIDENCE
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Finerenone (BAY94-8862 ) 10 mg
Intervention (Drug)
Empagliflozin
Intervention (Drug)
Empagliflozin Placebo
Intervention (Drug)
Finerenone (BAY94-8862 ) 20 mg
Intervention (Drug)
Finerenone Placebo
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct05254002
Content hash
68ff3b198ca60c735dec4f3ae6a372bd2eb0d96ab5194d5c124af847b73a6ead